度他雄胺 Dutasteride × 良性攝護腺肥大 (BPH) / 下泌尿道症狀 (LUTS)
結論：證據支持但有警示
Dutasteride × BPH 在所有可用 evidence layers 上呈現高度收斂的 S-tier 支持：L2 為 4 篇高品質研究（2014 SR 9 RCTs IPSS Δ -1.
B 🟡 B 初步證據 附警語發布 ⚠️ medium — moderate promotional content
Dutasteride × BPH 在所有可用 evidence layers 上呈現高度收斂的 S-tier 支持：L2 為 4 篇高品質研究（2014 SR 9 RCTs IPSS Δ -1.78 / Qmax +1.27 / TPV -17.4 cm³；CombAT n=4844 4 年 RCT 確認 combo 優於單方；REDUCE n=6729 PCa RRR 22.8% + AUR RRR 77.3%；2022 SR/MA n=2116 vs finasteride Qmax 略優），L4a FDA (Avodart NDA 021319/2001、Jalyn NDA 022460/2010) + L4c NHS/BNF + L4d TFDA 三大監管機構均核可 BPH 為唯一 on-label 適應症，L5b/c/d 三大臨床中心一致以標準用藥語氣描述（treats / decreases the size，非 may help），L5e AUA 2021 指引以 Strong Recommendation / Grade A（Statements 14、18 進展預防與合併療法）+ Moderate Recommendation / Grade B（Statement 13 單方 >30g 攝護腺）正式列為一線治療選項。
Dutasteride 對 5α-還原酶第 1+2 型雙重抑制（DHT 抑制 ~93–95% vs finasteride ~70%）在攝護腺體積縮減上具藥理優勢。
L1 Examine 不可用（Rx 藥不在 Examine scope），不影響判讀。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.69
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
88%
證據方向一致性高
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.694
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
The efficacy and safety of dutasteride and finasteride in patients with BPH: a systematic review and meta-analysis
結論：Dutasteride significantly superior to finasteride on Qmax (MD=0.32 mL/s, 95% CI 0.01-0.63, p=0.04); no significant difference on IPSS (p=0.70), PV (p=0.23), QoL (p=0.08), PSA (p=0.50), or ADRs (p=0.72).
前往 PubMed
Efficacy and safety of dutasteride for the treatment of symptomatic BPH: a systematic review and meta-analysis
結論：Dutasteride superior to placebo: IPSS Δ=-1.78 (95% CI -3.01 to -0.55), Qmax Δ=+1.27 mL/s (95% CI 0.97-1.57), TPV Δ=-17.40 cm³ (95% CI -25.77 to -9.02); adverse events RR 1.35 (95% CI 1.19-1.54). Dutasteride+tamsulosin > tamsulosin alone.
前往 PubMed
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year results from the CombAT study
結論：Combination therapy significantly superior to tamsulosin monotherapy at reducing AUR or BPH-related surgery, and superior to either monotherapy for clinical progression and symptom relief at 4 years; cardiac failure imbalance noted across arms.
前往 PubMed
Effect of dutasteride on the risk of prostate cancer (REDUCE trial)
結論：Dutasteride reduced PCa detection (659/3305 vs 858/3424; RRR 22.8%, 95% CI 15.2-29.8, p<0.001) and AUR (RRR 77.3%; 1.6% vs 6.7%); however, in years 3-4 Gleason 8-10 tumors were 12 vs 1 (p=0.003), and cardiac failure was higher (0.7% vs 0.4%, p=0.03).
前往 PubMed
L4a US FDA
支持
AVODART is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: improve symptoms, reduce the risk of acute urinary retention (AUR), and reduce the risk of the need for BPH-related surgery. AVODART is not approved for the prevention of prostate cancer. 來源↗
L4b EU EFSA
未表態
— 本適應症無對應資料
L4c UK NHS
謹慎
Dutasteride. Indications and dose — Benign prostatic hyperplasia. By mouth. For adult: 500 micrograms once daily, review treatment at 3–6 months and then every 6–12 months. ... Contra-indications: Women; children. ... Cautions: Patients should be assessed for prostate cancer before treatment and at regular intervals afterwards — dutasteride reduces serum prostate specific antigen (PSA) concentr… 來源↗
L4d TW TFDA / 衛福部
謹慎
Dutasteride（適尿通 Avodart 0.5mg 軟膠囊）為醫師處方用藥，核可適應症為良性攝護腺肥大（BPH），仿單載明可能引起性功能障礙（性慾減退、勃起功能障礙、射精異常）及男性乳房異常變化等不良反應，部分症狀於停藥後仍可能持續。 來源↗
L4e WHO
未表態
Finasteride and dutasteride: prostate cancer (WHO Drug Information / WHO Pharmaceuticals Newsletter signal communication) 來源↗
L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
支持
Dutasteride is used alone or in combination with tamsulosin (Flomax) to treat men who have symptoms of an enlarged prostate gland, which is also known as benign prostatic hyperplasia (BPH). Dutasteride blocks the action of an enzyme called 5-alpha-reductase. This enzyme changes testosterone to another hormone that causes the prostate to grow. As a result, the size of the prostate is decreased. 來源↗
L5c Cleveland Clinic
支持
Dutasteride treats the symptoms of an enlarged prostate (benign prostatic hyperplasia). This medication decreases the size of your prostate. 來源↗
L5d Harvard Health
支持
dutasteride (Avodart) or finasteride (Proscar) are used to treat 來源↗
L5e Specialty Society (condition-mapped)
支持
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 中度
低中高
📍立場總覽
台灣社群對度他雄胺(適尿通)討論量中等，但多集中在雄性禿（off-label）而非攝護腺肥大本身；BPH 相關討論散見於 Mobile01 攝護腺版與 PTT Doctor-Info。鄉民對排尿症狀改善反應分歧——多人認為有效但須持續服用 6-12 個月才見效，最大共同焦慮是性功能副作用（性慾下降、勃起與射精障礙、少數男性女乳症）。多數為真實患者求助與經驗分享，業配密度中等。
💬社群實感
分歧（多人認同對夜尿/頻尿與縮小攝護腺有效，但須長期服用才見效；對性功能副作用怨言多）
破解迷思 社群最常見的 4 個誤解
✓
事實以為吃了排尿症狀會很快改善（實際需 6-12 個月攝護腺體積才明顯縮小）
✓
事實把度他雄胺(適尿通)與非那雄胺(波斯卡/柔沛)混為一談，以為兩者完全相同（度他雄胺為 type I+II 雙重抑制、半衰期長很多）
✓
事實誤以為性功能副作用一定永久不可逆（社群多數案例停藥數週至數月內恢復，少數例外）
✓
事實不知道長期服用會使 PSA 數值約降一半，誤以為攝護腺癌風險已排除
🩹 社群通報的副作用
- 性慾下降
- 勃起功能障礙
- 射精障礙/精液量減少
- 男性女乳症/乳房脹痛
- 停藥後副作用多可恢復（部分人反映需數週至數月）
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- 適尿通 (Avodart, GSK)
- 適尿通膠囊 (學名藥/健保給付版)
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- Alpha 阻斷劑
- 5-α 還原酶抑制劑
- 經尿道攝護腺切除術等手術治療
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-bph-INT-dutasteride-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "度他雄胺能改善良性攝護腺肥大 (BPH) / 下泌尿道症狀 (LUTS)",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 3,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟡 B 初步證據"
}
}